Characterizing the role of mitochondrial DNA mutations on retinal degeneration.
- Institution
- CLEVELAND CLINIC LERNER COM-CWRU, OH
- Principal investigator
- Johnathon Brian Sturgis
- Funding
- $50K
- Duration
- 2024–2027
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY: Retinal cell health is a vital aspect of ophthalmic biology allowing us to see the world around us every day. Degeneration of the retina and/or retinal pigment epithelium (RPE) is a central cause of numerous clinical eye disorders such as age-related macular degeneration, retinitis pigmentosa, or glaucoma. Recent investigation into disease etiology has implicated oxidative stress and mitochondrial dysfunction as key players in the initiation of an unhealthy retina. More specifically, analysis of primary tissue from human donors have shown increases in mitochondrial DNA (mtDNA) mutations in these samples. This study uses novel pre-clinical models to test the hypothesis that impaired mitochondrial function due to mtDNA damage results in age-related retinal and RPE degeneration. To address this hypothesis we are utilizing polymerase gamma (Pol γ) as a tool to study the impact of mtDNA mutation burden on retinal health in both animal and cellular models. Previously developed mutated versions of Pol γ have shown to drastically increase mtDNA mutation rate, rendering this an effective method to analyze the impact mtDNA mutations have on specific biological mechanisms. The goal of this proposal is to determine the contribution mtDNA damage has on the onset and progression of retinal degeneration. This study will pinpoint how mitochondrial dysfunction and oxidative stress driven by mtDNA mutations promote an unhealthy state of the retina. Successful completion of this study will not only offer deeper mechanistic understanding of retinal disease, but may also open a novel avenue for therapeutic targeting.
LOADING MOONBASE SCORE
Questions for CLEVELAND CLINIC LERNER COM-CWRU
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Cleveland Clinic Lerner Com-Cwru66
Immune cell activation and associated blood brain barrier changes across different stages of Alzheimer's disease
Jagan Ayyappan Pillai · $738K · 2022–2028
- NIH · Cleveland Clinic Lerner Com-Cwru63
Host and microbe-dependent mechanisms of enhanced autoimmune susceptibility driven by checkpoint inhibitors
Vanessa Salazar · $55K · 2023–2026
- NIH · Cleveland Clinic Lerner Com-Cwru57
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Xiaojuan Li · $767K · 2020–2026